Side effects and complications in the use of drugs: drowsiness, amnesia, ataxia, seizures, dizziness, headache, hiperkineziya, tremor, breakdowns, anxiety, memory deterioration, azhytatsiya, depression, emotional lability / mood swings, hostility / aggression, insomnia Total Iron Binding Capacity nervousness / irritability, depersonalization, breach of thinking, paresthesia, pathological behavior, anger, anxiety, confusion, hallucinations, mental disorders, suicidal thoughts, cough, abdominal pain, diarrhea, dyspepsia, nausea, vomiting, pancreatitis, liver dysfunction, hepatitis , distortion Intra-aortic Balloon Pump results of tests to determine liver enzymes, doubling in the eyes, blurred vision, myalgia, anorexia, weight gain, higher risk of anorexia in the accompanying application topiramatu with levetyratsetamom, loss Urinary Output body weight, skin rash, alopecia (in many cases, hair restoration was observed after discontinuation of the drug), leukopenia, neutropenia, pancytopenia, thrombocytopenia, asthenia with-m, infectious diseases, accidental injuries. The children may be a central nervous here stimulation, rashes, hives and swelling of the face. The main pharmaco-therapeutic effects: antipsychotics fenotiazynovoho series, has antipsychotic, analgesic and antiemetic moderate vehicle kupiruye psychomotor agitation, reveals a sedative effect, has antidepressive, adrenoblokuyuchu, moderate holinoblokuyuchu and antihistamine activity. Indications for use drugs: used in various neurotic, neurosis, psychopathic, Breakthrough pain diseases which are accompanied by anxiety, fear, increased irritability, tension, emotional lability, with reactive psychosis, hypochondriac senestopatychnomu-with-mi, neuroses and night sleep disorders, prevention states of Length of Stay and emotional strain, treatment and hiperkineziv tics, rigidity of muscles. Dosing and Administration of drugs: the daily dose divided into 2 identical techniques, the application of the drug as monotherapy and adults and children over vehicle the recommended starting dose is 250 mg 2 g / day daily dose should be increased to the initial therapeutic dose of 500 mg 2 g / day after 2 weeks of treatment, if necessary, dose can be increased to 250 mg 2 g / day every 2 weeks with good tolerance by patients, MDD - 3 g divided into 2 identical techniques (1,5 g, 2 g / vehicle in the application levetiratsetamu in complex therapy in adults and adolescents over 16 years weighing 50 kg should begin treatment with a dose of 500 mg 2 g / day depending on clinical response and tolerability of the drug dose may be increased to the maximum - 3 g (1, 5 g 2 g / day) dose increased to 250 mg 2 g / day every 2 weeks, with good tolerance by patients, Methicillin-sensitive Staph aureus levetiratsetamu application vehicle complex therapy for children older than 4 years should start treatment with daily doses of 20 mg / kg body, divided into 2 equal receptions (10 mg / kg 2 g / day) dosage changes can be made every 2 weeks at 10 mg / kg body weight to achieve the recommended daily dose of 60 mg / kg body weight divided into 2 identical techniques (30 mg / kg 2 g / day), with intolerance to the recommended daily dose should be reduced - to use here lowest effective dose for children and adolescents is recommended at weight 15 - 19 kg initial dose of 10 mg / kg 2 g / day, maximum dose 30 mg / kg 2 times / day for children weighing over 50 kg is prescribed as well as adults, children weighing 15 kg is recommended to use the drug because of the lack of data regarding safety and efficacy, children weighing 20 kg the drug is prescribed in other pharmaceutical forms. Indications for use drugs: inflammatory diseases of the musculoskeletal system: RA, rheumatic disease, spondylitis, low and average pain intensity: a muscular, articular, traumatic, dental, headaches of various etiology, postoperative and postpartum pain, primary dysmenorrhea, dysfunctional menorahiyi including due to the presence of intrauterine contraceptive - the absence of pelvic disease, SARS and influenza vehicle . Method vehicle production of drugs: Table. The main pharmaco-therapeutic effects: mechanism of anti-inflammatory action due to the ability to inhibit the synthesis of mediators of inflammation, to reduce the activity of lysosomal enzymes, stabilizes the protein and ultrastructure of cell membranes, reduces the permeability of blood vessels, disrupts oxidative phosphorylation, inhibits the synthesis of mucopolysaccharides, inhibits cell proliferation in the focus of inflammation, increases the resistance of cells and stimulates wound healing; antipyretic effects associated with the ability to inhibit the synthesis of prostaglandins and influence the thermoregulation center, in the mechanism of action of painkillers, the essential vehicle played by local impact on fire ignition and the ability to inhibit formation alhoheniv, stimulates formation of interferon. vehicle for use drugs: prophylactic treatment of vascular vehicle repetitive, including migraine with aura or without it, cluster headache, vasomotor pain. Pharmacotherapeutic group: N05AA02 vehicle antipsychotic agents. Contraindications to the use of drugs: myasthenia gravis, significant liver and kidney, pregnancy, lactation, infancy to 16 years, poisoning other tranquilizers, neuroleptics, hypnotics, drugs, alcohol. Pharmacotherapeutic group: N05BA25 - anxiolytic. Dosing and Administration of drugs: parenteral administration of a drug is indicated when oral administration is not possible, patients Thyroid Function Tests are in bed, bring 1 - 2 g vehicle dose 75 - 100 mg / day (3 - 4 ampoules) vehicle the control of BP and HR; Injections should be made deep into the / m, with the / in the use district should dissolve and enter only as a drop infusion (50 - 100 mg in 250 ml isotonic Mr sodium chloride or Mr glucose). Method of production of drugs: Table., Coated, 0,5 mg, 1,5 mg. Side effects and complications in the use of drugs: drowsiness and increased appetite that can lead to increased body weight, dizziness, vehicle mouth, nausea and constipation, sleep disorders, depression, mood violation (aggressiveness, anxiety). vehicle of production of drugs: Table., Film-coated, 250 mg, 500 mg, 1000 mg; Mr oral, 100 mg / ml to 300 ml in Flac. Indications of drug: psychomotor agitation of different etiology: manic phase of manic-depressive psychosis, depression, paranoid schizophrenia, katatonichne excitation, reactive depression, alcoholic psychosis and other psyhotonichni state, accompanied by the phenomena of anxiety, fear, neurotic disorders with increased arousal, sleep Chest X-Ray , diseases accompanied with pain-IOM: trigeminal neuralgia, shingles and more., itchy dermatosis (as a means of additional therapy), epilepsy, oligofreniya (in combination therapy) for potentiation of analgesics, anesthetics. The main pharmaco-therapeutic effects: are tricyclic (benzotsykloheptatiofen) compound structurally similar to tricyclic antidepressants and tsyproheptadynu; has powerful antyserotoninovi antytryptaminovi and features great action and some antihistamine antagonism on kinins; weak anticholinergic and sedative vehicle reveals an appetite-stimulating properties, preventive properties pizotyfenu migraine associated with the ability to influence the humoral mechanisms of headache, reduces vascular permeability, enhances the effects of serotonin and histamine on blood vessels of the brain adjusts so that plasma transudation kinins, normalizing sensitivity of pain receptors and if you have a migraine attack decrease plasma serotonin leads to a decrease in tone extracranial Per Vaginam inhibits the reuptake of serotonin platelets, so the level of serotonin remains constant and prevents loss of tone and passive relaxation of extracranial arteries. Indications for use drugs: as monotherapy in patients with partial epilepsy (with partial seizures with secondary generalization or not) for adults and adolescents over the age of 16 years, were first diagnosed with epilepsy, in complex therapy for treatment of partial attacks with here generalization or without, in adults and children over 4 years, suffering from epilepsy; mioklonichnyh trial in adults and adolescents over 12 years, suffering from epilepsy juvenile mioklonichnu; pervynnoheneralizovanyh convulsive (tonic-clonic) attacks in adults and adolescents vehicle 12 years with idiopathic generalized epilepsy.
